^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective, single arm, open label, phase II clinical trial for anti-PD-1 antibody shr-1210 combined with first-line chemotherapy in the treatment of stage III gastric cancer (PD-L1 + / MSI-H / EB +)
Excerpt:
...Detection of biomarkers in postoperative gastric cancer samples suggests that: PD-L1 + CPS >=10% / MSI-H + / EB+; 6. ...
Trial ID:
Source:
Title:
An exploratory clinical study of camrelizumab combined with chemotherapy in the first-line treatment of MSI-H/dMMR advanced gastric cancer
Excerpt:
...Biopsy tissue immunohistochemistry (IHC) showed mismatch repair defects (dMMR) or gene sequencing results MSI status is microsatellite highly unstable (MSI-H); 6. ...
Trial ID:
More C2 evidence
Source:
Title:
A Single-Arm, Single-Center, Phase II Study Evaluating the Efficacy and Safety of Camrelizumab in the Adjuvant Treatment of MSI-H Locally Advanced Gastric Carcinoma
Excerpt:
...The microsatellite status is MSI-H; 5. ...
Trial ID:
Source:
Title:
A single arm and single center open clinical study of PD-1 antibody SHR-1210 in the microsatellite highly unstable (MSI-H) advanced solid tumor
Excerpt:
...A malignant solid tumor diagnosed by histology or cytology, with a partial advanced stage can not resection or metastasis; And the detection of tumor tissue by a third party confirmed MSI-H or dMMR; 3. ...
Trial ID:
Less C2 evidence
Source:
Title:
Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial
Published date:
07/04/2020
Excerpt:
...we explored the efficacy and safety of a PD-1 checkpoint inhibitor camrelizumab in advanced or metastatic solid tumour with dMMR/MSI-H....Disease control rate reached 100% (95% CI 73.5–100). Progression-free survival rate at 12 months was 83.3% (95% CI 48.2–95.6), and overall survival rate at 12 months was 90% (95% CI 47.3–98.5).
DOI:
10.1007/s00432-020-03251-5
Source:
Title:
Camrelizumab in advanced or metastatic solid tumor patients with microsatellite instability–high/mismatch repair-deficient: Results from an open-label exploratory study.
Published date:
05/28/2020
Excerpt:
Camrelizumab resulted in encouraging objective response and tolerable toxicity in MSI-H/dMMR advanced or metastatic solid tumor.
DOI:
10.1200/JCO.2020.38.15_suppl.e15140
